XML 29 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, PPE, Licensing and Research (Details) - USD ($)
1 Months Ended 3 Months Ended
Oct. 31, 2014
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Research and Product Development        
Product development and research costs   $ 1,214,851 $ 1,314,430  
Investments Available for Sale        
Fair value of investments   40,840,581   $ 40,759,703
Gross unrealized losses   789,875    
Realized gains   $ 0    
Baxter Healthcare Organization        
Revenue Recognition        
Initial Payment Received $ 20,000,000